

10. (amended) The method of claim 1, wherein said composition is administered systemically.

11. (amended) A method of <sup>to inhibit?</sup> preventing development of atherosclerosis in a subject, comprising administering to said subject a composition comprising cystatin C.

12. (amended) The method of claim 11, wherein said subject is at risk of developing atherosclerosis.

B<sup>3</sup> 13. (amended) A method of treating atherosclerosis in a subject, comprising administering to said subject a composition comprising transforming growth factor beta 1.

14 (twice amended) A method of <sup>^</sup> preventing development <sup>^</sup> of atherosclerosis in a subject, comprising administering to said subject a composition comprising transforming growth factor beta 1.

R126 22  
15. (new) A method of treating or preventing atherosclerosis in a subject, comprising administering to said subject a composition comprising a polypeptide of SEQ ID NO:3.

B<sup>4</sup> 23  
16. (new) A method of treating or preventing atherosclerosis, comprising identifying a subject suffering from or at risk of developing an atherosclerosis disease and administering to said subject a composition comprising cystatin C.

#### REMARKS

14-22-23  
Upon entry of this amendment, claims 1, 9-16 are pending in the instant application. Claims 15 and 16 are new. The present amendments are fully supported by the specification. No new matter has been added.

#### 1. Objection to the Information Disclosure Statement